344 view and meta-analysis of randomized trials. Biol Blood Marrow Transplant. 2016;22(6):1133–1137. doi: 10.1016/j.bbmt.2016.02.021. [30] Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald GB, Deeg HJ, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113(13):2888–2894. doi: 10.1182/blood-2008-07-168401. [31] Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75(4):1024– 1030. [32] MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroid as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8(7):387–394. doi: 10.1053/bbmt.2002.v8.pm12171485. [33] Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1–37. doi: 10.1111/jdv.12311. [34] Denney HA, Whittle RJ, Lai J, Jacques RM, Taylor PC. Regulatory T cells in chronic graft-versus-host disease after extracorporeal photopheresis: correlation with skin and global organ responses, and ability to taper steroids. Transplantation. 2017;101(1):204–211. doi: 10.1097/TP.0000000000001165. [35] Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91(3):405– 408. [36] Alousi AM, Basset R, Chen J, Overman BJ, Hosing CM, Popat UR, et al. A Bayesian, phase ii randomized trial of extracorporeal photopheresis (ECP) plus steroids versus steroids-alone in patients with newly diagnosed acute graft vs. host disease (GVHD): the addition of ECP improves GVHD response and the ability to taper steroids. Blood. 2015;126:854. [37] Inagaki J, Kodama Y, Fukano R, Noquchi M, Okamura J. Mycophenolate mofetil for treatment of steroid-refractory acute graft versus host disease after pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2015;19(6):652–658. doi: 10.1111/petr.12545. [38] Hattori K, Doki N, Kurosawa S, Hino Y, Yamamoto K, Sakaguchi M, et al. Mycophelonate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versushost disease after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017;96(2):319–321. doi: 10.1007/s00277-0162854-0. [39] Yang J, Cheuk DK, Ha SY, Chiang AK, Lee TL, Ho MH, et al. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2012;16(7):771–778. doi: 10.1111/j.1399-3046.2012.01756.x. [40] Nogueira MC, Azevedo AM, Pereira SC, Ferreira JL, Lerner D, Lobo AM, et al. Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease. Braz J Med Biol Res. 2007;40(12):1623–1629. doi: 10.1590/S0100879X2006005000145. [41] Motiló C, Ferrà C, Lopez L, Morgades M, Battle M, Ribera JM. Salvage treatment with infliximab of steroid-resistant graft-versus-host disease in allogeneic transplanted patients. Med Clin (Barc) 2011;137(3):115–118. doi: 10.1016/j.medcli.2011.03.006. [42] Tao T, Ma X, Yang J, Zou JY, Ji SM, Tan YS, et al. Humanized anti-CD-25 monoclonal antibody treatment of steroid-refractory acute graft-versus-host disease: a Chinese single-center experience in a group of 64 patients. Blood Cancer J. 2015;5(4):e308. doi: 10.1038/bcj.2015.33. [43] MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versushost disease. Biol Blood Marrow Transplant. 2002;8(1):40–46. doi: 10.1053/bbmt.2002.v8.pm11858189. [44] Nishimoto M, Nakamae H, Koh H, Nakamae M, Hirose A, Hayashi Y, et al. Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin. Exp Hematol. 2015;43(3):177–179. doi: 10.1016/j.exphem.2014.11.008. [45] Schlaak M, Schwind S, Wetzig T, Maschke J, Treudler R, Basara N, et al. UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant. 2010;45(12):1741– 1748. doi: 10.1038/bmt.2010.230. [46] Garbutcheon-Singh KB, Fernández-Pe as P. Phototherapy for the treatment of cutaneous graft versus host disease. Australas J Dermatol. 2015;56(2):93–99. doi: 10.1111/ajd.12191. [47] Feldstein JV, Bola os-Meade J, Anders VL, Abuav R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol. 2011;65(4):733–738. doi: 10.1016/j.jaad.2010.08.006. [48] Ivama S, Murase K, Sato T, Hashimoto A, Tatekoshi A, Horiguchi H, et al. Narrowband ultraviolet B phototherapy ameliorates acute graft-versus-host disease by a mechanism involving in vivo expansion of CD4+CD25+Foxp3+ regulatory T cells. Int J Hematol. 2014;99(4):471–476. doi: 10.1007/s12185-014-1530-1. [49] von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, et al. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome. Stem Cells (2016) 34:357–66. doi: 10.1002/stem.2224 [50] Aggarwal S, Pittenger MF. Human Mesenchymal Stem Cells Modulate Allogeneic Immune Cell Responses. Blood (2005) 105:1815–22. doi: 10.1182/blood-2004-04-1559 [51] Kelly K, Rasko JEJ. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.761616 [52] Bader P, Kuci Z, Bakhtiar S, Basu O, Bug G, Dennis M, et al. Effective Treatment of Steroid and Therapy-Refractory Acute Graft-Versus-Host Disease With a Novel Mesenchymal Stromal Cell Product (MSC-FFM). Bone Marrow Transplant (2018) 53:852– 62. doi: 10.1038/s41409-018-0102-z [53] Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease. Biol Blood Marrow Transplant (2020) 26:845– 54. doi: 10.1016/j.bbmt.2020.01.018
RkJQdWJsaXNoZXIy ODUzNzk5